Bet v 1 contiguous overlapping peptides anchored to virosomes with TLR4 agonist enhance immunotherapy efficacy in mice

Airouche, Sabi; Beltrami, Vanya; Fleury, Sylvain; Batard, Thierry; Floch, Véronique Bordas-Le; Stegmann, Toon; Amacker, Mario; Kettner, Alexander; Mascarell, Laurent

doi:10.1111/cea.13814

Cited by 3 publications

(2 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Promising clinical results have already been obtained with therapeutic vaccination using SLPs targeting HPV16 E6 and E7 oncoproteins combined with chemotherapy in cervical cancer [ 4 ] [ 2 ] and combined with anti-PD-1 in head & neck cancer [ 35 , 36 ], using Montanide as an adjuvant (2) Modification of the peptides with Amplivant fosters induction of Th1 T helper responses and sustained and robust CTL responses [ 37 ]. (3) Virosomes are nanoparticles that are particularly effective at presenting a variety of antigens, from HIV proteins and peptides to allergy-related antigens [ 19 , 21 ]. Virosomes without adjuvant containing soluble HPV 16 E7 protein in the lumen of the virosomes can induce CD8 + T cells and prevent tumor outgrowth in a prophylactic vaccination model [ 38 ].…”

Section: Discussionmentioning

confidence: 99%

“…Influenza virosomes retain the hemagglutinin protein (HA) of the virus, which promotes the uptake of the virosomes by APCs and the delivery of antigens to the cytosol by fusion between the endosomal and the virosomal membrane [ 17 , 18 ]. Virosomes can be produced with peptide or protein antigens covalently linked to lipids of the membrane to induce strong immune responses against those antigens [ 19 – 21 ] and have been marketed as influenza and Hepatitis A vaccines [ 16 , 22 ]. Virosomes have been shown to induce strong CTL responses [ 23 , 24 ], and virosomes presenting the HPV16 E7 protein induced the survival of vaccinated mice challenged with TC-1 cells [ 18 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Enhanced HPV16 E6/E7+ tumor eradication via induction of tumor-specific T cells by therapeutic vaccination with virosomes presenting synthetic long peptides

Stegmann¹,

Wiekmeijer

Kwappenberg

et al. 2023

Cancer Immunol Immunother

Self Cite

View full text Add to dashboard Cite

Therapeutic cancer vaccines trigger CD4 + and CD8 + T cell responses capable of established tumor eradication. Current platforms include DNA, mRNA and synthetic long peptide (SLP) vaccines, all aiming at robust T cell responses. SLPs linked to the Amplivant® adjuvant (Amplivant-SLP) have shown effective delivery to dendritic cells, resulting in improved immunogenicity in mice. We have now tested virosomes as a delivery vehicle for SLPs. Virosomes are nanoparticles made from influenza virus membranes and have been used as vaccines for a variety of antigens. Amplivant-SLP virosomes induced the expansion of more antigen-specific CD8 + T memory cells in ex vivo experiments with human PBMCs than Amplivant-SLP conjugates alone. The immune response could be further improved by including the adjuvants QS-21 and 3D-PHAD in the virosomal membrane. In these experiments, the SLPs were anchored in the membrane through the hydrophobic Amplivant adjuvant. In a therapeutic mouse model of HPV16 E6/E7+ cancer, mice were vaccinated with virosomes loaded with either Amplivant-conjugated SLPs or lipid-coupled SLPs. Vaccination with both types of virosomes significantly improved the control of tumor outgrowth, leading to elimination of the tumors in about half the animals for the best combinations of adjuvants and to their survival beyond 100 days.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Enhanced HPV16 E6/E7+ tumor eradication via induction of tumor-specific T cells by therapeutic vaccination with virosomes presenting synthetic long peptides

Stegmann¹,

Wiekmeijer

Kwappenberg

et al. 2023

Cancer Immunol Immunother

Self Cite

View full text Add to dashboard Cite

show abstract

Current advances in house dust mite allergen immunotherapy (AIT): Routes of administration, biomarkers and molecular allergen profiling

Batard

Canonica

Pfaar

et al. 2023

Molecular Immunology

View full text Add to dashboard Cite

Birch Pollen Allergens

Guan

Chang

2022

CPPS

View full text Add to dashboard Cite

Birch belongs to order Fagales and family Betulaceae. Birch pollen is one of the most important airborne inhaled allergens in the north temperate zone, leading to allergic rhinitis, asthma and pollen-related food allergy. The sensitization rate to birch pollen is about 8-16% in the general populations and 7-57% in patients seen at various allergy centers. Seven birch pollen allergens have been recognized by the International Allergen Nomenclature Sub-committee, with Bet v 1 as the sole major allergen. Component-resolved diagnostics can help to discriminate broad cross-reactivity and false-positive diagnoses of pollen allergy caused by specific IgE to pan-allergens such as Bet v 2, 4 or Bet v 7 from true birch allergy represented by the major allergen Bet v 1-specific IgE. Patients with allergic symptoms to birch pollen showed significantly higher serum anti-Bet v 1 IgE concentrations than asymptomatic individuals with birch sensitization. Higher level of IgE to Bet v 1 also predicted oral allergy syndrome after the ingestion of Rosaceae fruits, nuts, or Apiaceae vegetables, which have cross-reactive homologous allergens with birch allergens. Bet v 1 is one of the first allergens developed using recombinant technology. Many forms of genetically modified Bet v 1 hypo-allergens have been developed and have shown benefit in animal models or even clinical trials of allergen immunotherapy.

show abstract

Bet v 1 contiguous overlapping peptides anchored to virosomes with TLR4 agonist enhance immunotherapy efficacy in mice

Cited by 3 publications

References 30 publications

Enhanced HPV16 E6/E7+ tumor eradication via induction of tumor-specific T cells by therapeutic vaccination with virosomes presenting synthetic long peptides

Enhanced HPV16 E6/E7+ tumor eradication via induction of tumor-specific T cells by therapeutic vaccination with virosomes presenting synthetic long peptides

Current advances in house dust mite allergen immunotherapy (AIT): Routes of administration, biomarkers and molecular allergen profiling

Birch Pollen Allergens

Contact Info

Product

Resources

About